• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15923 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Turoctocog alfa - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benefit assessment of an HPV test in primary screening for cervical cancer - Rapid report]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Second Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic guideline search and appraisal, as well as extraction of new and relevant recommendations, for the DMP "breast cancer"]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Canagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-05 (sofosbuvir)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pilot study: conjoint analysis in the indication "hepatitis C"]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Riociguat - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cholic acid - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dimethyl fumarate - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-12 (canagliflozin)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Siltuximab - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Determination of antigen expression levels of uPA and PAI-1 in primary breast cancer with intermediate recurrence risk after R0 primary surgery]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Simeprevir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirabegron - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment and analysis of studies on rare diseases - Rapid report]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sperm analysis parameters as an indication for intracytoplasmic sperm injection (ICSI) instead of in vitro fertilization (IVF)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stents for the treatment of intracranial artery stenosis - Rapid report]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-14 (dimethyl fumarate)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Regular exploratory examination of the need for DMP revision - a feasibility study using the example of the DMP "CHD"]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vedolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Umeclidinium/vilanterol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-19 (mirabegron)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-18 (simeprevir)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinituzumab - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Canagliflozin/metformin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nalmefene - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teduglutide - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Propranolol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daclatasvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-21 (Fingolimod)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (extension of approval) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/abacavir/lamivudine - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sucroferric oxyhydroxide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idelalisib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Albiglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipuleucel-T - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcorneal electrical stimulation for retinitis pigmentosa]
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Arthroscopy for knee osteoarthritis: review of clinical evidence and guidelines
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Herniorrhaphy for inguinal and femoral hernia: review of clinical evidence and guidelines
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Spinal surgery for chronic low back pain: review of clinical evidence and guidelines
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Centralisation of bariatric surgery: policy implications
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Stem cell transplantation for biologic-resistant Crohn's disease
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Remote presence robots in telemedicine
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Ablative techniques for the treatment of localised prostate cancer
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Theralite for treatment of renal failure in patients with multiple myeloma
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Drug-eluting stents with CD34 antibodies for the treatment of coronary artery disease
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Online programs for weight loss
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Sutureless aortic valve replacement in patients with severe aortic valve stenosis
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Balloon sinuplasty for chronic rhinosinusitus
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Implantable carotid sinus baroreflex device for treatment of drug resistant hypertension
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Basic fibroblast growth factor (b-FGF) for the treatment of tympanic membrane perforation
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) New and emerging orthopaedic technologies in the Australian and New Zealand public health services
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Miethke proSA adjustable gravitational shunt for hydrocephalus
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) HPV OncoTect E6, E7 mRNA assay to guide colposcopy referral in cervical cancer screening
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) SentiMag and Sienna+ for sentinel lymph node localisation in breast cancer
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Neonatal screening for lysosomal storage disorders
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Out of hours emergency coronary angiography and/or coronary angioplasty and stenting
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Final protocol to guide the assessment of magnetic resonance imaging of liver lesions
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Consultation protocol to guide the assessment of foot and ankle services by podiatric surgeons
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Local anaesthetic (LA) nerve blockade for post-surgical analgesia
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation therapy
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Insertion of subcutaneous electrode for the purpose of use with an implantable cardioverter defibrillator (ICD)
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Ear, nose and throat services - surgical services for obstructive sleep apnoea
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) MBS reviews paediatric services male circumcision services review report
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Gastrointestinal liner ('EndoBarrier') to treat diabetes and obesity
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Single dose stereotactic radiosurgery for benign or malignant intracranial tumours (Gamma Knife)
2014 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Ultrasound imaging in the practice of anaesthesia
2014 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of measures related to the prevention of multiple falls in hospitalized elderly people]
2014 National Institute for Health and Care Excellence (NICE) Teriflunomide for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 303
2014 National Institute for Health and Care Excellence (NICE) Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip. NICE technology appraisal guidance 304
2014 National Institute for Health and Care Excellence (NICE) Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion. NICE technology appraisal guidance 305
2014 National Institute for Health and Care Excellence (NICE) Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma. NICE technology appraisal guidance 306
2014 National Institute for Health and Care Excellence (NICE) Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy. NICE technology appraisal guidance 307
2014 National Institute for Health and Care Excellence (NICE) Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. NICE technology appraisal guidance 308
2014 National Institute for Health and Care Excellence (NICE) Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 310
2014 National Institute for Health and Care Excellence (NICE) Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. NICE technology appraisal guidance 311
2014 National Institute for Health and Care Excellence (NICE) Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 312
2014 National Institute for Health and Care Excellence (NICE) Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure. NICE technology appraisal guidance 314
2014 National Institute for Health and Care Excellence (NICE) Canagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance 315
2014 National Institute for Health and Care Excellence (NICE) Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen. NICE technology appraisal guidance 316
2014 National Institute for Health and Care Excellence (NICE) Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes. NICE technology appraisal guidance 317
2014 National Institute for Health and Care Excellence (NICE) Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 319
2014 National Institute for Health and Care Excellence (NICE) Dimethyl fumarate for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 320
2014 National Institute for Health and Care Excellence (NICE) Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma. NICE technology appraisal guidance 321